[go: up one dir, main page]

WO2012120522A1 - Comprimé de sildénafil à mâcher au goût masqué - Google Patents

Comprimé de sildénafil à mâcher au goût masqué Download PDF

Info

Publication number
WO2012120522A1
WO2012120522A1 PCT/IN2011/000138 IN2011000138W WO2012120522A1 WO 2012120522 A1 WO2012120522 A1 WO 2012120522A1 IN 2011000138 W IN2011000138 W IN 2011000138W WO 2012120522 A1 WO2012120522 A1 WO 2012120522A1
Authority
WO
WIPO (PCT)
Prior art keywords
sildenafil
taste masked
chewable tablet
tablet
pharmaceutical excipient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IN2011/000138
Other languages
English (en)
Inventor
Deepak Murpani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GENEPHARM INDIA PRIVATE Ltd
Original Assignee
GENEPHARM INDIA PRIVATE Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GENEPHARM INDIA PRIVATE Ltd filed Critical GENEPHARM INDIA PRIVATE Ltd
Priority to PCT/IN2011/000138 priority Critical patent/WO2012120522A1/fr
Publication of WO2012120522A1 publication Critical patent/WO2012120522A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms

Definitions

  • the present invention relates to taste masked chewable tablet of sildenafil useful in the treatment of pulmonary hypertension and erectile dysfunction.
  • Sildenafil is a selective inhibitor of cyclic guanosine monophosphate (cGMP)- specific phosphodiesterase type 5 (PDE5), marketed by Pfizer. Sildenafil is designated chemically as l-[[3-(6, 7-dihydro-l-methyl-7- oxo-3-propyl-l -pyrazolo[4,3-d] pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4- methyl piperazine.
  • cGMP cyclic guanosine monophosphate
  • PDE5 phosphodiesterase type 5
  • the pharmaceutically acceptable salt of sildenafil, sildenafil citrate has a very bitter taste and hence tablets which are commercially available are film coated.
  • the film coating masks any bitter taste in the mouth.
  • taste masking of sildenafil by coating with polymers is already known in the art.
  • United States Patent No. 6,221,402 (assigned to Pfizer referred to herein as '402 patent) discloses a rapidly releasing and taste masking pharmaceutical dosage form of sildenafil and a process of its preparation.
  • the dosage form has an inner and outer coating wherein the inner coating coats the core of sildenafil citrate and low-substituted hydroxypropylcellulose and the outer coating comprises a saliva-insoluble polymer.
  • PCT publication WO 2004087111 discloses oral taste masked pharmaceutical compositions that include a core having an active ingredient coated with a mixture of polymeric film forming binders and inorganic carriers. Processes for preparing the oral taste masked pharmaceutical composition are also provided.
  • PCT publication WO2009074995 (assigned to M/S Ajanta Pharma Limited referred to herein as '995 publication) relates to tablets comprising sildenafil mask complex. However, the tablets comprise additional taste masking pharmaceutical excipient like monoammonium glycerrhizinate for masking the bitter taste of sildenafil citrate.
  • the process for the preparation of the tablets involves wet granulation which could degrade sildenafil.
  • the present invention relates to chewable tablets without additional taste masking pharmaceutical excipient and is prepared under anhydrous conditions.
  • PCT Symposium on M/S Ocean, referred to herein as '626 publication relates to orodispersible tablets of phosphodiesterase -5 inhibitors including sildenafil.
  • the amount of disintegrant used is more than 5% of weight of tablet.
  • process for the preparation of tablets utilizes organic solvent in the moist granulation procedure.
  • the present invention relates to chewable tablets which comprises less than 5% of disintegrant and is prepared under anhydrous conditions and in the absence of organic solvent.
  • the object of the present invention is to provide a taste masked chewable tablet of sildenafil and the process of its preparation.
  • a taste masked chewable tablet of sildenafil comprising
  • the present invention provides a taste masked chewable tablet of sildenafil.
  • the taste masked chewable tablet of sildenafil comprises complex of sildenafil with divinylbenzene methacrylate prepared in the absence of organic solvent and directly compressible pharmaceutical excipient(s) wherein the tablets are obtainable by method under anhydrous conditions
  • Anhydrous conditions may, be selected from compaction, direct compression and dry granulation.
  • the directly compressible pharmaceutical excipient may be selected from diluents, binders, lubricants, disintegrants, flavoring agents, coloring agents, stabilizers, surfactants, glidants, plasticizers, preservatives and sweeteners.
  • Diluents may be selected from calcium carbonate, calcium phosphate dibasic, calcium phosphate tribasic, calcium sulfate, microcrystalline cellulose, microcrystalline silicified cellulose, powdered cellulose, dextrates, dextrose, fructose, lactitol, lactose anhydrous, lactose monohydrate, lactose dihydrate, lactose trihydrate, starch, pregelatinized starch, sucrose, talc, maltose maltodextrin.
  • Binders may be selected from acacia, alginic acid, carbomer, carboxymethylcellulose calcium, carbomethylcellulose sodium, microcrystalline cellulose,powdered cellulose, ethyl cellulose, gelatin liquid glucose, guar gum, hydroxyethyl cellulos, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, maltodextrin, methylcellulose, ploydextrose, polyethtylene oxide,povidone, sodium alginate, starch paste, pregelatinized starch, sucrose, tragacanth, low-substituted hydroxypropyl cellulose,glucose, sorbitol.
  • Suitable fillers are preferably selected from atleast one of starch derivatives.such as com starch, potato starch or rice starch.
  • starch derivatives such as com starch, potato starch or rice starch.
  • Polysaccharides such as dextrins, maltodextrins, dextrates, microcrystalline cellulose, powdered cellulose, mixture of microcrystalline cellulose and guar gum, coprocessed blends of microcrystalline cellulose; and polyhydric alcohols, such as xylitol and sorbitol.
  • Lubricants may be selected from magnesium stearate, stearic acid, sodium stearyl fumarate, magnesium lauryl sulphate, talc, polyethylene glycol, and glyceryl behenate.
  • Disintegrants may be selected from, alginic acid, carbon dioxide, carboxymethylcellulose, calcium carboxymethylcellulose sodium, microcrystalline cellulose, powdered cellulose, croscarmelose sodium, crospovidone, sodium docusate, gaur gum, hydroxypropyl cellulose, methylcellulose, polacrilin potassium , poloxamer, povidone, sodium alginate, sodium glycine carbonate, sodium laulyl sulfate, sodium starch glycolate, starch, pregelatinized starch, low-substituted hydroxypropyl cellulose.
  • the amount of disintegrant used is preferably less than 5% by weight of the tablet, more preferably 3-5% by weight of the tablet.
  • Flavoring agents may be selected from natural or synthetic flavors such as strawberry flavor, wild cherry flavor, green apple flavor, spearmint flavor and peppermint flavor.
  • Glidarits may be, for example, calcium silicate, powdered cellulose, starch, talc, colloidal silicon dioxide.
  • Suitable sweeteners may be selected from sugars such as sucrose, lactose and glucose; cyclamate and salts thereof; saccharin and salts thereof; and aspartame.
  • the directly compressible pharmaceutical excipient used in the present invention will not comprise sugar alcohol.
  • the directly compressible pharmaceutical excipient used in the present invention will not comprise organic acid.
  • the directly compressible pharmaceutical excipient used in the present invention will not comprise . monoammonium glycerhizinate
  • the taste masked chewable tablet of sildenafil is triangular in shape.
  • the dimensions of the tablets of the present invention may be as follows
  • the process for the preparation of taste masked chewable tablet of sildenafil or its pharmaceutically acceptable salt is also provided.
  • a process for the preparation of taste masked chewable tablet of sildenafil comprising
  • the process of the present invention for preparing sildenafil complex with crosslinked polymer of divinylbenzene methacrylate is carried out in the absence of organic solvent like ethanol and the like. Further, the process of mixing sildenafil complexed with crosslinked polymer of divinylbenzene methacrylate with directly compressible pharmaceutical excipient(s) will not comprise water or an organic solvent like isopropyl alcohol.
  • anhydrous conditions for step (b) may be selected from dry granulation, compaction and direct compression.
  • the tablets prepated by the process of the present invention may be triangular in shape.
  • the dimensions of the tablets of the present invention may be as follows
  • the pH of dispersion is adjusted with addition of hydrochloric acid to pH 5 4 ⁇ 0.5 under stirring with or without heating.
  • the pH of dispersion is adjusted with addition of hydrochloric acid to pH 5 4 ⁇ 0.5 under stirring with or without heating.

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)

Abstract

Comprimé de sildénafil à mâcher au goût masqué et son procédé de préparation.
PCT/IN2011/000138 2011-03-04 2011-03-04 Comprimé de sildénafil à mâcher au goût masqué Ceased WO2012120522A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/IN2011/000138 WO2012120522A1 (fr) 2011-03-04 2011-03-04 Comprimé de sildénafil à mâcher au goût masqué

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IN2011/000138 WO2012120522A1 (fr) 2011-03-04 2011-03-04 Comprimé de sildénafil à mâcher au goût masqué

Publications (1)

Publication Number Publication Date
WO2012120522A1 true WO2012120522A1 (fr) 2012-09-13

Family

ID=46797563

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2011/000138 Ceased WO2012120522A1 (fr) 2011-03-04 2011-03-04 Comprimé de sildénafil à mâcher au goût masqué

Country Status (1)

Country Link
WO (1) WO2012120522A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140077658A (ko) * 2012-12-14 2014-06-24 한미약품 주식회사 포스포다이에스터라제-5 억제제를 포함하는 츄정
CN104248625A (zh) * 2013-06-25 2014-12-31 北大方正集团有限公司 阿伐那非泡腾干混悬剂及其制备方法
WO2014209022A1 (fr) * 2013-06-28 2014-12-31 Hanmi Pharm. Co., Ltd. Formule de comprimé à mâcher comprenant du tadalafil ou l'un de ses sels pharmaceutiquement acceptables
CN113271949A (zh) * 2018-10-26 2021-08-17 阿尔特罗亚公司 用于治疗骨关节炎的西地那非

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060127479A1 (en) * 2004-10-08 2006-06-15 Natrajan Kumaraperumal Solvent free taste masked pharmaceutical compositions
WO2009123626A1 (fr) * 2008-04-01 2009-10-08 Ocean 1 806, Llc Formulations dispersables par voie orale d'inhibiteurs de la phosphodiestérase-5 (pde-5)
WO2010115576A1 (fr) * 2009-04-06 2010-10-14 Ratiopharm Gmbh Comprimé orodispersible contenant un sel de sildénafil
EP2338474A1 (fr) * 2009-12-23 2011-06-29 Ratiopharm GmbH Comprimé orodispersible contenant une base de sidénafil compactée

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060127479A1 (en) * 2004-10-08 2006-06-15 Natrajan Kumaraperumal Solvent free taste masked pharmaceutical compositions
WO2009123626A1 (fr) * 2008-04-01 2009-10-08 Ocean 1 806, Llc Formulations dispersables par voie orale d'inhibiteurs de la phosphodiestérase-5 (pde-5)
WO2010115576A1 (fr) * 2009-04-06 2010-10-14 Ratiopharm Gmbh Comprimé orodispersible contenant un sel de sildénafil
EP2338474A1 (fr) * 2009-12-23 2011-06-29 Ratiopharm GmbH Comprimé orodispersible contenant une base de sidénafil compactée

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140077658A (ko) * 2012-12-14 2014-06-24 한미약품 주식회사 포스포다이에스터라제-5 억제제를 포함하는 츄정
KR101953735B1 (ko) * 2012-12-14 2019-03-04 한미약품 주식회사 포스포다이에스터라제-5 억제제를 포함하는 츄정
CN104248625A (zh) * 2013-06-25 2014-12-31 北大方正集团有限公司 阿伐那非泡腾干混悬剂及其制备方法
CN104248625B (zh) * 2013-06-25 2016-12-28 北大方正集团有限公司 阿伐那非泡腾干混悬剂及其制备方法
WO2014209022A1 (fr) * 2013-06-28 2014-12-31 Hanmi Pharm. Co., Ltd. Formule de comprimé à mâcher comprenant du tadalafil ou l'un de ses sels pharmaceutiquement acceptables
KR20150002453A (ko) * 2013-06-28 2015-01-07 한미약품 주식회사 타다라필 또는 이의 약학적으로 허용가능한 염을 포함하는 저작정 제제
KR102239291B1 (ko) 2013-06-28 2021-04-14 한미약품 주식회사 타다라필 또는 이의 약학적으로 허용가능한 염을 포함하는 저작정 제제
CN113271949A (zh) * 2018-10-26 2021-08-17 阿尔特罗亚公司 用于治疗骨关节炎的西地那非

Similar Documents

Publication Publication Date Title
ES2347968T3 (es) Preparacion solida que se disgrega rapidamente.
JP6730978B2 (ja) 固形製剤
PT1123088E (pt) Formulações farmacêuticas de libertação controlada contendo um cgmp inibidor de pde-5
WO2007074856A1 (fr) Procede de production de preparation solide se desintegrant dans la cavite orale
JPWO2009096560A1 (ja) イミダフェナシン含有口腔内速崩壊性錠剤
JP2020518611A (ja) 水溶解度及びバイオアベイラビリティが改善された組成物
WO2012120522A1 (fr) Comprimé de sildénafil à mâcher au goût masqué
TWI574690B (zh) 立即釋放４－甲基－３［［４－（３－吡啶基）－２－嘧啶基］胺基］－ｎ－［５－（４－甲基－１ｈ－咪唑－１－基）－３－（三氟甲基）苯基］苯甲醯胺調配物
HUP0200646A2 (hu) Magas N-acetilcisztein-tartalmú lenyelhető tabletták
WO2023195953A1 (fr) Comprimé pelliculé comprenant du selexi̇pag
JP2017048174A (ja) 化学的に安定な原薬含有被覆粒子を含む口腔内崩壊錠剤
CN112384223A (zh) 含有难溶性碱性药剂的药物组合物
US20110028480A1 (en) Orodispersable formulations of phosphodiesterase-5 (pde-5) inhibitors
CN114246835A (zh) 一种枸橼酸西地那非口腔崩解片的制备方法
WO2011093828A2 (fr) Formes posologiques solides comprenant du cefprozil
JP7322474B2 (ja) アジルサルタンを含有する錠剤
WO2021091498A1 (fr) Compositions pharmaceutiques comprenant du ténofovir et de l'emtricitabine
US10722469B2 (en) Method for preparing pharmaceutical composition comprising quinoline derivative or salt thereof
RU2201751C1 (ru) Фармацевтическая композиция, обладающая антигипертензивным и диуретическим действием, и способ её получения
CN105616376B (zh) 含异甘草酸镁药物的组合物及制备方法
WO2019151964A2 (fr) Formulations de saxagliptine à délitement buccal
US20100272800A1 (en) Orally disintegrating olanzapine tablet
EP3694519A2 (fr) Combinaison pharmaceutique comprenant de la dapoxétine et de la phosphodiestérase de type 5
EP2959889A1 (fr) Formulations de loxoprofen se désintégrant par voie orale
EP2962685B1 (fr) Formulations de tadalafil se désintégrant par voie orale

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11860231

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11860231

Country of ref document: EP

Kind code of ref document: A1